Interview part two: Chang Yi Wang, Chairperson & CEO, UBI Asia, and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.
The company’s product pipeline is filled with a new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on UBI’s proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. The company’s platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire.
UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by the company’s subsidiary UBI-Asia and various sponsorships in product development.
Rm. E, 52F., No.7-5,
Sec. 5, Xinyi Rd.,
Xinyi Dist.,
Taipei City
11049,
Taiwan (R.O.C.)
Tel:886-2-8101-0101
Fax:886-2-8101-0100
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in…
TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take,…
An expert perspective on the possibilities of self-pay markets in Taiwan, and the opportunities afforded by bringing manufacturing of medical technology to the country, for export to the region. Uni-Pharma…
You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is…
A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of…
The President of Gene Health, a company specialized in genomics testing, talks about the current market situation for genomic testing, and building the business in the Chinese market, as well…
The Director General of one of the world’s most successful science parks discusses the history of the park, the reasons behind its incredible success, the unique set-up of the park…
In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths,…
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
The General Director of the ‘Invest in Taiwan’ program discusses Taiwan’s competitiveness on a global and regional level, highlights the areas and industrial sectors where the country is looking to…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
See our Cookie Privacy Policy Here
